AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8429114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg, twice daily)
Number of subjects: 10
Study 8429114 — intervention group
Group type: COMPARATOR
Intervention: Enoxacin alone
Number of subjects: 10
Study 31677703 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (15 mg/d)
Number of subjects: 75
Study 31677703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29247154 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) 2 mg/kg administered intravenously at weeks 0, 4, 12, and every 8 weeks
Number of subjects: 208
Study 29247154 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) 2 mg/kg administered intravenously
Number of subjects: 208
Study 29247154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) administered intravenously
Number of subjects: 208
Study 26391697 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free fixed-dose combination (FDC) of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 15
Study 26391697 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost 0.0015%
Number of subjects: 15
Study 26391697 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free timolol 0.5%
Number of subjects: 15
Study 24524229 — intervention group
Group type: EXPERIMENTAL
Intervention: Full PopART combination HIV prevention package including annual home-based HIV testing, promotion of medical male circumcision for HIV-negative men, and offer of immediate ART for those testing HIV-positive
Number of subjects: 2500
Study 24524229 — intervention group
Group type: EXPERIMENTAL
Intervention: Full package except that ART initiation will follow current national guidelines
Number of subjects: 2500
Study 24524229 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2500
Study 22296864 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX-STR
Number of subjects: 191
Study 22296864 — intervention group
Group type: COMPARATOR
Intervention: DOX-RIF
Number of subjects: 191
Study 22296864 — intervention group
Group type: COMPARATOR
Intervention: OFX-RIF
Number of subjects: 191
Study 20309777 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional help sheet with explicit instructions to link occasions of temptation with behavioral responses
Number of subjects: 68
Study 20309777 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a questionnaire and a volitional help sheet without explicit instructions
Number of subjects: 68
Study 18057976 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intense physical exercise in normobaric hypoxia (15 vol.% O2)
Number of subjects: 32
Study 18057976 — intervention group
Group type: COMPARATOR
Intervention: Low intense physical exercise in normobaric sham hypoxia (20.1 vol.% O2)
Number of subjects: 32
Study 15837835 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 or 25 mg orally for 2 months)
Number of subjects: 0
Study 15837835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (dosage not specified, orally for 2 months)
Number of subjects: 0
Study 15837835 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 12478352 — intervention group
Group type: EXPERIMENTAL
Intervention: DD genotype of ACE gene in VUR patients with renal scarring (44%)
Number of subjects: 77
Study 12478352 — intervention group
Group type: EXPERIMENTAL
Intervention: D allele frequency in VUR patients with scarred kidneys (0.64)
Number of subjects: 77
Study 12478352 — intervention group
Group type: EXPERIMENTAL
Intervention: I allele frequency in VUR patients with scarred kidneys (0.36)
Number of subjects: 77
Study 10073373 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility analysis among patients with schizophrenia
Number of subjects: 0
Study 7538244 — intervention group
Group type: EXPERIMENTAL
Intervention: LN-SV-TPP
Number of subjects: 22
Study 7538244 — intervention group
Group type: COMPARATOR
Intervention: RRP
Number of subjects: 22
Study 2288297 — intervention group
Group type: EXPERIMENTAL
Intervention: YN-72 30 mg/day
Number of subjects: 226
Study 2288297 — intervention group
Group type: EXPERIMENTAL
Intervention: YN-72 150 mg/day
Number of subjects: 226
Study 2288297 — intervention group
Group type: EXPERIMENTAL
Intervention: YN-72 300 mg/day
Number of subjects: 226
Study 2288297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 7191314 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 64
Study 7191314 — intervention group
Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 64
Study 30691157 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Track Socio-Economic Development (SED) intervention
Number of subjects: 87
Study 30691157 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 30691157 — intervention group
Group type: EXPERIMENTAL
Intervention: SED clients
Number of subjects: 87
Study 27752075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folinic acid (2 mg kg-1 per day, maximum 50 mg per day; n=23)
Number of subjects: 48
Study 27752075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 48
Study 26966984 — intervention group
Group type: EXPERIMENTAL
Intervention: Card game 1
Number of subjects: 0
Study 26966984 — intervention group
Group type: EXPERIMENTAL
Intervention: Card game 2
Number of subjects: 0
Study 26966984 — intervention group
Group type: EXPERIMENTAL
Intervention: Card game 3
Number of subjects: 0
Study 26966984 — intervention group
Group type: EXPERIMENTAL
Intervention: Card game 4
Number of subjects: 0
Study 24649525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid monitoring with target < 2 mmol/L
Number of subjects: 57
Study 24649525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid monitoring
Number of subjects: 57
Study 22727138 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT; V.A.C.® Therapy; KCI USA, Inc.)
Number of subjects: 0
Study 21284136 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 21284136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16908126 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Number of subjects: 259
Study 16908126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 15741820 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 303
Study 15741820 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tartrate 0.2% twice daily
Number of subjects: 303
Study 15741820 — intervention group
Group type: COMPARATOR
Intervention: Comparison of latanoprost vs brimonidine
Number of subjects: 303
Study 15741820 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 303
Study 14507154 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment approaches for fixation of mandibular fractures
Number of subjects: 834
Study 14507154 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 834
Study 9445241 — intervention group
Group type: EXPERIMENTAL
Intervention: Satigrel
Number of subjects: 9
Study 9445241 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 9
Study 7875025 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Ondansetron 8 mg IV infusion before CDDP, followed by 8 mg tablets in the afternoon and before sleeping on the first day, then 3 tablets of 8 mg daily for the next 3 days.
Number of subjects: 90
Study 7875025 — intervention group
Group type: COMPARATOR
Intervention: Group B: Ondansetron 8 mg IV infusion on the first day, followed by the same regimen as Group A.
Number of subjects: 90
Study 2151197 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 1 mg to 16 mg once daily
Number of subjects: 40
Study 2151197 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg to 100 mg once daily
Number of subjects: 40
Study 365801 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin combined with sodium salicylate
Number of subjects: 0
Study 365801 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 0
Study 31370950 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≤55 years
Number of subjects: 10
Study 31370950 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥85 years
Number of subjects: 10
Study 29315129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block with 30 mL of ropivacaine 0.5% with 1:400,000 epinephrine
Number of subjects: 201
Study 29315129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block with active drug and 100 μg of ITM
Number of subjects: 201
Study 29315129 — intervention group
Group type: COMPARATOR
Intervention: Sham adductor canal block with 30 mL of normal saline
Number of subjects: 201
Study 27187300 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (3000 IU/kg)
Number of subjects: 448
Study 27187300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline, 0.9%)
Number of subjects: 448
Study 24568228 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based modules (10 modules over 4 weeks)
Number of subjects: 164
Study 24568228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 164
Study 22386051 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use nonablative fractional laser device (daily treatments during active phase, twice-weekly during maintenance phase)
Number of subjects: 124
Study 22386051 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use nonablative fractional laser device (twice-weekly treatments during maintenance phase)
Number of subjects: 124
Study 20068422 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks' exercise training
Number of subjects: 49
Study 17290311 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lung sport programme for 12 months
Number of subjects: 7
Study 17290311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sport)
Number of subjects: 7
Study 16051712 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance loading (RL) of knee extensors
Number of subjects: 38
Study 16051712 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance loading (RL) in older adults
Number of subjects: 38
Study 16051712 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance loading (RL)
Number of subjects: 38
Study 16051712 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels in older females vs young females
Number of subjects: 38
Study 12942250 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine dihydrochloride, phenoxyethanol (nonspecific mucosal antiseptic)
Number of subjects: 491
Study 12942250 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (specific topical antifungal agent)
Number of subjects: 491
Study 10397513 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial periodontal therapy and gingival curettage
Number of subjects: 31
Study 10397513 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral hygiene instructions only)
Number of subjects: 31
Study 8893679 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF)
Number of subjects: 116
Study 8893679 — intervention group
Group type: COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 116
Study 1387475 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (single dose)
Number of subjects: 16
Study 6381003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 8
Study 6381003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 8
Study 31219404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-depletion (experimental) group (n=26)
Number of subjects: 51
Study 31219404 — intervention group
Group type: COMPARATOR
Intervention: Non-ego-depletion (control) group (n=25)
Number of subjects: 51
Study 28714180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.i.d.
Number of subjects: 58
Study 28714180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d.
Number of subjects: 58
Study 28714180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25945764 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium fluoride (SF) 0.11%
Number of subjects: 32
Study 25945764 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (PG)
Number of subjects: 32
Study 24378865 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-triage kiosk group
Number of subjects: 200
Study 24378865 — intervention group
Group type: COMPARATOR
Intervention: Standard nurse triage group
Number of subjects: 200
Study 21129822 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use metal laryngoscope blades
Number of subjects: 817
Study 21129822 — intervention group
Group type: COMPARATOR
Intervention: Reusable metal laryngoscope blades
Number of subjects: 817
Study 19719736 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged implants
Number of subjects: 30
Study 19719736 — intervention group
Group type: COMPARATOR
Intervention: Non-submerged implants
Number of subjects: 30
Study 17402869 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led interactive program
Number of subjects: 16
Study 17402869 — intervention group
Group type: COMPARATOR
Intervention: Standard program
Number of subjects: 16
Study 15072249 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleting filter
Number of subjects: 50
Study 15072249 — intervention group
Group type: COMPARATOR
Intervention: Control filter
Number of subjects: 50
Study 12828139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Number of subjects: 85
Study 12828139 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 85
Study 9821908 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck collar (intervention group)
Number of subjects: 15
Study 9821908 — intervention group
Group type: COMPARATOR
Intervention: No neck collar (control group)
Number of subjects: 15
Study 8027158 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioception enhancement programme (P)
Number of subjects: 50
Study 8027158 — intervention group
Group type: COMPARATOR
Intervention: Muscle strengthening programme (T)
Number of subjects: 50
Study 8027158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (P and T)
Number of subjects: 50
Study 2547028 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (120 mg/m2)
Number of subjects: 162
Study 2547028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide (100 mg/m2 on days 1, 2, and 3)
Number of subjects: 162
Study 192510 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (100 mg, three times daily)
Number of subjects: 7
Study 192510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 192510 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0-20 microng/min after placebo; 0-80 microng/min after practolol)
Number of subjects: 7
Study 192510 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (0-20 microng/min in the placebo phase; 0-16 microng/min in the practolol phase)
Number of subjects: 7
Study 31776880 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocelectomy with excision of the sac using LigaSure™ device
Number of subjects: 82
Study 31776880 — intervention group
Group type: COMPARATOR
Intervention: Jaboulay's technique
Number of subjects: 82
Study 30341058 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive nucleos(t)ide analog treatment (NAT)
Number of subjects: 326
Study 30341058 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic nucleos(t)ide analog treatment (NAT)
Number of subjects: 326
Study 30341058 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA monitoring-guided preemptive NAT
Number of subjects: 326
Study 30341058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic NAT
Number of subjects: 326
Study 30341058 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable HBV DNA at baseline
Number of subjects: 326
Study 29093506 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction Factor (IF) method
Number of subjects: 0
Study 29093506 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic modelling
Number of subjects: 0
Study 29093506 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical relationship between IF and overlap
Number of subjects: 0
Study 29093506 — intervention group
Group type: EXPERIMENTAL
Intervention: ImageJ plugin for IF determination
Number of subjects: 0
Study 26005166 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nursing intervention to detect cognitive and emotional problems, provide information and support, promote self‐management, and refer to specialised care
Number of subjects: 185
Study 26005166 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nursing intervention
Number of subjects: 185
Study 26005166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 185
Study 25910292 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C with steatosis + NAFLD (Group 2)
Number of subjects: 405
Study 25910292 — intervention group
Group type: COMPARATOR
Intervention: IBD + dyspepsia + hepatitis C without steatosis (Group 1)
Number of subjects: 405
Study 25910292 — intervention group
Group type: EXPERIMENTAL
Intervention: Group with fatty liver
Number of subjects: 405
Study 25910292 — intervention group
Group type: COMPARATOR
Intervention: Group without fatty liver
Number of subjects: 405
Study 21923418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar hybrid surgery
Number of subjects: 86
Study 21923418 — intervention group
Group type: COMPARATOR
Intervention: Bipolar resection of the prostate
Number of subjects: 86
Study 19328023 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU unfractionated heparin (UFH)
Number of subjects: 183
Study 19328023 — intervention group
Group type: COMPARATOR
Intervention: 2500 IU low molecular weight heparin (LMWH, dalteparin)
Number of subjects: 183
Study 19328023 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 183
Study 19328023 — intervention group
Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 183
Study 17366247 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to visits (attended >= 80% of visits)
Number of subjects: 458
Study 17366247 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to treatment (took >= 80% of pills)
Number of subjects: 458
Study 17366247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lost to follow-up (missed >= 3 consecutive visits)
Number of subjects: 458
Study 17366247 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics of nonadherent women
Number of subjects: 458
Study 17366247 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics of women lost to follow-up
Number of subjects: 458
Study 15111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive biopsy using intravenous conscious sedation (IVCS) (24 biopsies)
Number of subjects: 197
Study 15111980 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1)
Number of subjects: 197
Study 11495824 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1,600 mg/d
Number of subjects: 144
Study 11495824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 9514482 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 2964
Study 8071036 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide (300 mg I/mL)
Number of subjects: 140
Study 8071036 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 140
Study 8071036 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 140
Study 1761485 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ppm H2S
Number of subjects: 16
Study 1761485 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 ppm H2S
Number of subjects: 16
Study 1761485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 ppm H2S
Number of subjects: 16
Study 1761485 — intervention group
Group type: COMPARATOR
Intervention: Control (0 ppm H2S)
Number of subjects: 16
Study 35428 — intervention group
Group type: EXPERIMENTAL
Intervention: Andursil
Number of subjects: 1106
Study 35428 — intervention group
Group type: COMPARATOR
Intervention: Magnesium Trisilicate Co
Number of subjects: 1106
Study 31494176 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation Assessment Scale (CAS)
Number of subjects: 175
Study 31494176 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation treatments (1 to 2 per day)
Number of subjects: 175
Study 31494176 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation severity evaluation over 10 weeks
Number of subjects: 175
Study 31642581 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 104
Study 31642581 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI)
Number of subjects: 104
Study 28039653 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve block (PNB) with 4 ml (30 mg) of 0.75% ropivacaine (group P, n = 28)
Number of subjects: 60
Study 28039653 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n = 32)
Number of subjects: 60
Study 28039653 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve block (PNB)
Number of subjects: 60
Study 28039653 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 60
Study 26068548 — intervention group
Group type: EXPERIMENTAL
Intervention: α-keto acids (KAS) supplementation (0.2 g kg(‐1) body weight each day)
Number of subjects: 28
Study 26068548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23463772 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional function training + additional balance exercises
Number of subjects: 113
Study 23463772 — intervention group
Group type: COMPARATOR
Intervention: Conventional function training
Number of subjects: 113
Study 21455088 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine pretreatment/saline admixture
Number of subjects: 151
Study 21455088 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline pretreatment/lidocaine admixture
Number of subjects: 151